Navigation Links
Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
Date:4/10/2013

SAN DIEGO and UPPSALA, Sweden, April 10, 2013 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a clinical research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, and Mercodia AB, an industry-leading developer of immunoassays for metabolic clinical and research applications, jointly announced today a strategic alliance to include Mercodia's enzyme-linked immnosorbent assays (ELISA) as a component of Profil Institute's early phase clinical services. 

Both Profil Institute and Mercodia are widely recognized for their expertise in diabetes, obesity and cardiometabolic research.  Profil Institute is a center of excellence for early phase metabolic clinical research and is renowned for its expertise in proof of mechanism methods, including first-in-patient and automated glucose clamp studies, and its large patient recruitment database.  Mercodia is globally recognized for its robust ELISA assay development for metabolic clinical research and to study the pharmacokinetics of insulin and metabolic peptides.  Mercodia's assays will now be offered to Profil Institute's clients as a component of the clinical trial process. 

"With the addition of Mercodia's robust ELISA assays, we further enhance our wide scope of clinical research services, generating unprecedented investigative standards for early phase diabetes and obesity drug development," said Dr. Marcus Hompesch , Profil Institute CEO. "Our scientific understanding of diabetes and of the pharmacokinetic and pharmacodynamic effects of insulin, as well as our expertise working with all diabetes drug classes, enables us to provide highly conclusive data so that our clients can make the best decisions, as early as possible, about the further development of their drug candidates."

"We are very pleased to partner with Profil Institute and therefore combine our disease area expertise for a powerful outcome in the precision of clinical research data," said Mona Österberg, CEO of Mercodia AB.  "Together we will deliver greater scientific insight to Profil Institute's customers enhancing their overall metabolic drug development program at the earliest stage of clinical research in humans."

About Mercodia AB
Mercodia AB is a Swedish biotech company focusing on the development of highly reproducible and specific ELISA assays within the field of metabolic disorders.  Mercodia is a world-leading supplier to all major international markets and provides a professional scientific support system to develop novel applications for existing products and unique diagnostics for emerging markets.  The facilities include a GLP-compliant laboratory and a customized assay development core managed by our extensive quality system and ISO 13485 for manufacturing medical devices.  For more information visit www.mercodia.com.

About Profil® Institute for Clinical Research, Inc.
Profil Institute is internationally renowned as a Center of Excellence for early phase clinical research of drugs and devices for diabetes, obesity and cardiometabolic diseases. The company's scientific expertise, advanced metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute studies of far more complexity and have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug studies. Profil Institute has been involved with every clinically promising drug class in diabetes and in more than 175 clinical studies since the company's inception in 2004. For more information visit www.profilinstitute.com


'/>"/>
SOURCE Profil Institute for Clinical Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
2. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
3. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
4. Abaxis Announces the Launch of Kidney Profile Plus Panel
5. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
6. Group Florence Nightingale Increases Radiosurgery Profile with Acquisition of Turkeys First Leksell Gamma Knife Perfexion System
7. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
10. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
11. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
Breaking Medicine News(10 mins):